[go: up one dir, main page]

AR067627A1 - Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion - Google Patents

Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion

Info

Publication number
AR067627A1
AR067627A1 ARP080102744A ARP080102744A AR067627A1 AR 067627 A1 AR067627 A1 AR 067627A1 AR P080102744 A ARP080102744 A AR P080102744A AR P080102744 A ARP080102744 A AR P080102744A AR 067627 A1 AR067627 A1 AR 067627A1
Authority
AR
Argentina
Prior art keywords
alkyl
radical
attached
preparation procedure
compound
Prior art date
Application number
ARP080102744A
Other languages
English (en)
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of AR067627A1 publication Critical patent/AR067627A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/164—Unsaturated ethers containing six-membered aromatic rings
    • C07C43/168—Unsaturated ethers containing six-membered aromatic rings containing six-membered aromatic rings and other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Conjugados poliméricos basados en Fmoc (9-fluorofenil-metoxicarbonilo). Estos conjugado9s son utiles para extender la circulacion in vivo de drogas con proteínas y péptidos. Reivindicacion 1: Un compuesto de la formula 1 caracterizado porque Z es un grupo saliente y al menos uno de la posicion 1, 2, 3, 4, 5, 6, 7 u 8 está unido al radical Y; Y es un radical que contiene un biopolímero semi-sintético que está unido a una mitad N-succinimidilo; al menos uno de una posicion disponible 1, 2, 3, 4, 5, 6, 7 u 8 está unido opcionalmente al radical X; X es -SO3-R3; R3 está seleccionado independientemente del grupo que consiste en hidrogeno, alquilo C1-8 y alquil C1-8-R4; y R4 es un polímero. Reivindicacion 2: El compuesto de acuerdo con la reivindicacion 1, caracterizado porque Z es un éster de N-succinimidilo; Y es como en formula (2), polímero es un biopolímero semi-sintético; R1 es en cada caso independientemente un alquilo C1-8; y R2 es seleccionado independientemente del grupo que consiste en -C(O)NR-, -C(O)NR-alquil C1-8-NR-, -NRC(O)- y -NRC(O)-alquil C1-8-NR; R es independientemente hidrogeno o alquilo C1-8. Reivindicacion 14: Un conjugado caracterizado porque comprende el compuesto de cualquiera de las reivindicaciones 1 a 7 y una droga con proteína o péptido.
ARP080102744A 2007-06-26 2008-06-25 Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion AR067627A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93716907P 2007-06-26 2007-06-26
US12326308P 2008-04-07 2008-04-07

Publications (1)

Publication Number Publication Date
AR067627A1 true AR067627A1 (es) 2009-10-21

Family

ID=39855055

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102744A AR067627A1 (es) 2007-06-26 2008-06-25 Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion

Country Status (16)

Country Link
US (3) US7700551B2 (es)
EP (1) EP2173383B1 (es)
JP (1) JP5622569B2 (es)
KR (1) KR101654375B1 (es)
CN (1) CN101687048B (es)
AR (1) AR067627A1 (es)
AU (1) AU2008267360B2 (es)
BR (1) BRPI0813772A2 (es)
CA (1) CA2690554C (es)
DK (1) DK2173383T3 (es)
ES (1) ES2644453T3 (es)
HK (1) HK1142828A1 (es)
MX (1) MX2009013682A (es)
NZ (1) NZ582669A (es)
TW (1) TWI569810B (es)
WO (1) WO2009000522A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2101821B1 (en) 2006-12-15 2014-08-13 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
DK2173383T3 (en) * 2007-06-26 2017-09-25 Baxalta GmbH HYDROLYSIBLE POLYMERIC FMOC LINKER
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2597954T3 (es) 2009-07-27 2017-01-24 Baxalta GmbH Conjugados de proteína de la coagulación sanguínea
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
AU2012286048A1 (en) 2011-07-18 2014-02-20 Arts Biologics A/S Long acting luteinizing hormone (LH) compound
US20150133383A1 (en) 2012-05-11 2015-05-14 Prorec Bio Ab Method for diagnosis and treatment of prolactin associated disorders
CN103933575B (zh) * 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680295B1 (en) * 1994-09-22 2004-01-20 The Administrators Of The Tulane Educational Fund Method and pharmaceutical composition for prevention and treatment of brain damage
US6368814B1 (en) * 2000-12-22 2002-04-09 Roche Diagnostics Corporation Tricyclic antidepressant derivatives and immunoassay
PL1620118T3 (pl) * 2003-04-08 2014-11-28 Yeda Res & Dev Leki odwracalnie pegylowane
WO2005014655A2 (en) * 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
ES2294535T3 (es) * 2003-08-12 2008-04-01 Lipoxen Technologies Limited Derivados del acido polisialico.
JP4942014B2 (ja) * 2004-09-14 2012-05-30 独立行政法人産業技術総合研究所 Ｏ−結合型糖アミノ酸
BRPI0519562A2 (pt) * 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
US8252275B2 (en) * 2005-06-16 2012-08-28 Nektar Therapeutics Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
EP2101821B1 (en) * 2006-12-15 2014-08-13 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
JP5702066B2 (ja) * 2006-12-27 2015-04-15 ネクター セラピューティクス 解離可能な連結を有するフォンウィルブランド因子および第ｖｉｉｉ因子のポリマー共役体
DK2173383T3 (en) * 2007-06-26 2017-09-25 Baxalta GmbH HYDROLYSIBLE POLYMERIC FMOC LINKER

Also Published As

Publication number Publication date
TW200908996A (en) 2009-03-01
US20100121034A1 (en) 2010-05-13
CA2690554A1 (en) 2008-12-31
KR101654375B1 (ko) 2016-09-05
CN101687048A (zh) 2010-03-31
EP2173383A1 (en) 2010-04-14
CN101687048B (zh) 2013-02-27
WO2009000522A1 (en) 2008-12-31
AU2008267360A1 (en) 2008-12-31
US20100121028A1 (en) 2010-05-13
DK2173383T3 (en) 2017-09-25
US8445544B2 (en) 2013-05-21
TWI569810B (zh) 2017-02-11
BRPI0813772A2 (pt) 2014-12-30
JP2010531371A (ja) 2010-09-24
NZ582669A (en) 2011-07-29
EP2173383B1 (en) 2017-08-09
JP5622569B2 (ja) 2014-11-12
CA2690554C (en) 2016-08-16
US7700551B2 (en) 2010-04-20
MX2009013682A (es) 2010-08-31
US20090005542A1 (en) 2009-01-01
ES2644453T3 (es) 2017-11-29
HK1142828A1 (en) 2010-12-17
KR20100039854A (ko) 2010-04-16
AU2008267360B2 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
AR067627A1 (es) Enlazador fmoc polimerico hidrolizable. procedimiento de preparacion
BRPI0816405B8 (pt) complexos de rna e pepitídeos catiônicos para transfecção e para imunoestimulação
DE602007011901D1 (de) Ptiden und zellpenetrierenden peptiden gekoppelt a
EP2573110A3 (en) Peptide vaccines with Seq Id No: 174, 178, 186 or 194 for cancers expressing tumor-associated antigens
EP2810661A3 (en) Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
CY1118243T1 (el) Νεα κατασκευασματα μεταφορεα και μορια συζευγματος φορτιου μεταφορεα
ATE533514T1 (de) Verzweigtes polyethylen-glykol zur verknüpfung von polymerresten mit antikörpern
CY1114992T1 (el) Μονοδιεσπαρμενες πεγκυλιωμενες συνθεσεις ναλοξολης
AR055179A1 (es) Procedimiento para la amidacion de polipeptidos con aminoacidos de caracter basico c-terminales mediante el uso de endoproteasas especificas
BR112015004501A2 (pt) derivado de ácido hialurônico tendo aminoácidos e grupos esterila introduzidos no mesmo
CY1113684T1 (el) Anti-mikρobiaka πεπτιδια που περιλαμβανουν μια αργινινη (arginine)- kai/ή λυσινη (lysine)- που περιεχουν υποκινητη
DE502004012226D1 (de) Saugstent
CY1108752T1 (el) Παραγωγα πουρινης δρωντα ως αγωνιστες του α2α-υποδοχεα
MX2019005671A (es) Sustancias para direccionar diversos organos o tejidos seleccionados.
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
PE20091007A1 (es) Depsipeptidos ciclicos como moduladores de calicreina 7
KR20170085593A (ko) 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
US11191724B2 (en) Branched peptides for enzymatic assembly and mitochondria drug delivery
WO2011008863A8 (en) Stereoisomer peptides and their polymer conjugates for hiv disease
EP2481748A3 (en) Foxp3 peptide vaccine
AR067173A1 (es) Metodo para preparar ligadores hidrolizables basados en fmoc
ATE555120T1 (de) Neue antimikrobielle peptide und ihre anwendung
NI200700176A (es) Compuestos peptídicos
DOP2007000121A (es) Imidazolidina-2,4-dionas sustituidas con arilaminoarilalquilo, procedimiento para su preparación, medicamentos que comprenden estos compuestos y su uso
UY26492A1 (es) Bencimidazoles, su preparación y su empleo como medicamentos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure